Cellectis (CLLS) Income from Non-Controlling Interests (2015 - 2023)
Cellectis (CLLS) recorded quarterly Income from Non-Controlling Interests of -$4.9 million in Q2 2023, down 101.39% quarter-over-quarter from -$2.4 million in Q1 2023, and down 1075.1% on a YoY basis from $506000.0 in Q2 2022.
Cellectis (CLLS) Income from Non-Controlling Interests (2015 - 2023) Analysis & Trends
Cellectis' Income from Non-Controlling Interests history runs 8 years deep, the most recent figure standing at -$4.9 million for Q2 2023.
- In Q2 2023, Income from Non-Controlling Interests fell 1075.1% year-over-year to -$4.9 million; the TTM figure through Mar 2024 stood at -$4.9 million (up 23.93% YoY), while the FY2023 annual figure was -$7.4 million, up 6.46% from the prior year.
- Income from Non-Controlling Interests was -$4.9 million for Q2 2023 at Cellectis, down from -$2.4 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $506000.0 in Q2 2022 to a low of -$6.1 million in Q4 2020.
- Historically, Income from Non-Controlling Interests has averaged -$3.0 million across 5 years, with a median of -$3.1 million in 2019.
- The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests jumped 129.92% in 2022, then plunged 1075.1% in 2023.
- A 5-year view of Income from Non-Controlling Interests shows it stood at -$3.9 million in 2019, then sank by 55.09% to -$6.1 million in 2020, then surged by 49.63% to -$3.1 million in 2021, then soared by 43.45% to -$1.7 million in 2022, then slumped by 182.91% to -$4.9 million in 2023.
- The last three Income from Non-Controlling Interests figures came in at -$4.9 million (Q2 2023), -$2.4 million (Q1 2023), and -$1.7 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -4.93 Mn |
| Mar 31, 2023 | -2.45 Mn |
| Dec 31, 2022 | -1.74 Mn |
| Sep 30, 2022 | -2.80 Mn |
| Jun 30, 2022 | 506,000.00 |
| Mar 31, 2022 | -2.85 Mn |
| Dec 31, 2021 | -3.08 Mn |
| Sep 30, 2021 | -2.66 Mn |
| Jun 30, 2021 | -1.69 Mn |
| Mar 31, 2021 | -3.48 Mn |
| Dec 31, 2020 | -6.12 Mn |
| Sep 30, 2020 | -3.31 Mn |
| Jun 30, 2020 | -3.59 Mn |
| Mar 31, 2020 | -3.48 Mn |
| Dec 31, 2019 | -3.95 Mn |
| Sep 30, 2019 | -3.49 Mn |
| Jun 30, 2019 | -3.19 Mn |
| Mar 31, 2019 | -2.48 Mn |
| Dec 31, 2018 | -2.99 Mn |
| Sep 30, 2018 | -2.51 Mn |